ArticleTransboundary and emerging diseases2025
Recombinant PRV Expressing GP3 and GP5 of PRRSV Provides Effective Protection Against Coinfection With PRV and PRRSV.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing the Major Neutralizing Epitopes A and D of Transmissible Gastroenteritis Virus Spike Protein.Veterinary sciences · 2026Article
- A novel replication-deficient feline herpesvirus type 1 vector-based vaccine provides strong immune protection in cats.Journal of virology · 2026Article
- CD163 at the crossroads: a viral-exploited immunomodulator.Virology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine Reproductive and Respiratory Syndrome (PRRS) and Pseudorabies (PR) are highly contagious diseases caused by Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and Pseudorabies virus (PRV). Due to the limited protective ability of currently commercialized vaccines against NADC30-like PRRSV and PRV variants, the pathological damage caused by coinfection of these two viruses has a significant impact on China's pig farming industry. In this study, six recombinant PRV stains with TK and gI/gE deletions and fused expression of GM-CSF and GP3 and GP5 proteins from NADC30-Like PRRSV were constructed by using the HDR-CRISPR/Cas9
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.